VNDA

Tradipitant

Motion Sickness

Phase 3

Exp Date

TBD

Amp Volatility Score

Catalyst Info & Data Links

TITLE: Tradipitant for Motion Sickness

  • ClinicalTrial.gov (NCT03772340): (Phase 2 - Completed) Motion Sifnos: A Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion Sickness

  • ClinicalTrial.gov (NCT04327661): Motion Syros: A Randomized Study Investigating the Efficacy of Tradipitant in Treating Motion Sickness


WHAT IS THE NEXT CATALYST EVENT?

  • TBD

WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?

  • TBD


PRIOR DATA

PRESS RELEASES

MECHANSIM OF ACTION / RATIONALE

  • Tradipitant is an orally bioavailable, centrally-acting, selective, neurokinin 1 receptor (NK1-receptor; NK1R; NK-1R) antagonist with potential anti-emetic, anti-pruritic and anti-inflammatory activities. Upon oral administration, tradipitant competitively binds to and blocks the activity of the NK1R in the central nervous system (CNS), thereby inhibiting the binding of the endogenous ligand and neuropeptide, substance P (SP; neurokinin-1; NK1). This inhibits SP/NK1-mediated signal transduction and may prevent both SP-induced emesis and pruritis. In addition, inhibition of SP/NK1R signaling also reduces neurogenic inflammation which is triggered by the release of neuropeptides, such as substance P, from nerve cells. NK1R is a G protein-coupled receptor (GPCR) that preferentially binds to SP, a neuropeptide secreted by neuronal cells and inflammatory cells. (source - National Library of Medicine (National Institute of Health))

Updated by HC

#VNDA, #Tradipitant, #Motion_Sickness

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See What The Community Is Saying - Click To See Full Post

Upcoming September 2020 COVID-...

Check out our AmpCards & #COVID19 catalyst tracker for investible small & mid-cap biopharma companies in the COVID therapeutics and vaccine race. Therapeutic candidate data from $VNDA, $BCRX, & $BSGM ...

VNDA - Interim Analysis from #...

#VNDA's interim analysis of the #ODYSSEY study demonstrated that hospitalized patients with #COVID-19 pneumonia improved sooner when treated with #tradipitant as compared to placebo. Summary of find...

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon